Reduced intracellular accumulation of azole antifungal results in resistance in Candida albicans isolate NCPF 3363.
Candida albicans strain NCPF 3363 was isolated from a British patient with chronic mucocutaneous candidiasis (CMC) and confirmed to be resistant to azole antifungal compounds. In this study we investigate the molecular basis of resistance and show that azole tolerance in NCPF 3363 was associated with reduced intracellular accumulation of drug and not reduced affinity for the target site, as previously indicated. Relative impermeability or the presence of transporters related to those responsible for multidrug resistance are implicated in the mechanism of resistance.
Lamb
D C
DC
Krebs Institute for Biomolecular Research, Department of Molecular Biology and Biotechnology, Sheffield University, UK.
Kelly
D E
DE
Manning
N J
NJ
Kelly
S L
SL
D000935:Antifungal Agents / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use; D002176:Candida albicans / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism*; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D015725:Fluconazole / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use; D007654:Ketoconazole / Q000378:metabolism* / Q000494:pharmacology* / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D013261:Sterols / Q000302:isolation & purification
D000935:Antifungal Agents; D013261:Sterols; D015725:Fluconazole; D007654:Ketoconazole